Table 2.

Multivariate models of 12-month all-cause and cardiovascular mortality.

All-Cause Mortality	HR (95% CI)	P
PHQ-2 Status, (+) vs. (−)	3.1 (1.4–6.7)	0.003
Gender, female vs. male	1.3 (0.8–2.0)	0.28
Age ≥ 65 vs. <65	2.1 (1.3–3.4)	0.004
Ejection Fraction ≤ 30% vs. >30%	1.1 (0.6–1.7)	0.84
NYHA Class, III–IV vs. II	1.5 (0.9–2.6)	0.12
Anxiety disorder	0.8 (0.4–1.3)	0.33
Chronic obstructive pulmonary disease	1.1 (0.7–1.8)	0.72
Renal insufficiency	1.8 (1.1–2..9)	0.01
ACE-I or ARB use	0.6 (0.4–1.0)	0.04
Beta-blocker use	0.60 (0.3–0.9)	0.03
Coumadin use	0.9 (0.6, 1.4)	0.65
Diabetes	1.1 (0.7–1.7)	0.75
Hemoglobin <10 vs. ≥ 10 g/dL	1.4 (0.8–2.6)	0.26
Sodium, <136 vs. ≥ 136 mmol/L	1.4 (0.8–2.4)	0.18
Diastolic blood pressure, per 10-unit increase	1.1 (1.0–1.2)	0.27
Systolic blood pressure, per 10-unit increase	0.9 (0.9–1.0)	0.27
Cardiovascular Mortality	HR (95% CI)	P
PHQ-2 Status, (+) vs. (−)	2.7 (1.1–6.6)	0.03
Gender, female vs. male	1.4 (0.8–2.5)	0.21
Age ≥ 65 vs. <65	1.6 (0.9–2.9)	0.13
Ejection Fraction ≤ 30% vs. >30%	1.4 (0.7–2.8)	0.30
NYHA Class, III–IV vs. II	1.4 (0.7–2.7)	0.29
Anxiety disorder	0.9 (0.4–1.7)	0.70
Chronic obstructive pulmonary disease	1.1 (0.6–2.0)	0.69
Renal insufficiency	1.5 (0.9–2.8)	0.15
ACE-I or ARB use	0.4 (0.2–0.7)	0.003
Coumadin use	1.0 (0.6–1.7)	0.97
Beta-blocker use	0.6 (0.3–1.0)	0.05
Diabetes	1.5 (0.9–2.6)	0.17
Hemoglobin <10 vs. ≥ 10 g/dL	1.1 (0.5–2.4)	0.87
Sodium, <136 vs. ≥ 136 mmol/L	1.4 (0.8–2.8)	0.27
Diastolic blood pressure, per 10-unit increase	1.1 (1.0–1.2)	0.08
Systolic blood pressure, per 10-unit increase	0.9 (0.8–1.0)	0.09